Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
VANCOUVER, British Columbia, May 03, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time to provide a business update and review first quarter 2017 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760) 298-5082 (international). A live webcast will be available in the “Investors” section of Novelion’s website, www.novelion.com, and a replay will be available for 90 days after the conclusion of the event.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
